文献速递主动脉外科

Gore Conformable胸主动脉支架联合主动控制系统治疗主动脉弓及降主动脉疾病的结果分析

Outcome analysis of the Gore Conformable Thoracic Stent Graft with active control system for the treatment of arch and descending thoracic aortic disease.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

该单中心回顾性研究纳入2017至2020年115例使用Gore CTAG with ACS行TEVAR的患者,技术成功率95.7%,临床成功率80.9%,总体死亡率19.1%,急诊与择期死亡差异显著。ACS整体装置放置良好,但TEVAR仍具挑战且不良事件负担重。

要点

  • 技术成功率达95.7%(110/115)。
  • 急诊手术占47%,急诊与择期总体死亡率差异显著(P<0.001)。
  • ACS使用率40.9%,部署准确率87.8%,充分贴壁93.0%。

核心结论

  • CTAG with ACS在多种主动脉病变中表现令人鼓舞,ACS整体装置放置良好,但TEVAR仍具挑战且与疾病固有负担相关。

研究设计与样本

  • 单中心前瞻性维护数据库的回顾性分析,纳入2017至2020年115例连续TEVAR患者。

主要发现

  • 技术成功95.7%(110/115),临床成功80.9%(93/115),主要因手术相关死亡(n=14)。
  • 总体死亡率19.1%(22/115),急诊与择期差异显著(log-rank P<0.001)。
  • 手术相关严重不良事件率44.3%(51/115),手术相关再干预率20.9%(24/115)。
  • 再干预累积发生率在急诊与择期病例间差异显著(Gray's test P=0.0033)。
  • ACS用于40.9%(47/115)患者,多见于II型弓(52.7%);部署准确率87.8%(101/115),充分贴壁93.0%(107/115)。

临床怎么用

  • 对于弓部及降主动脉疾病,CTAG with ACS可获得较高的技术成功率和良好的装置放置。
  • 急诊TEVAR患者死亡风险显著高于择期,需充分评估并加强围术期管理。

局限性

  • 单中心回顾性研究,随访时间中位数仅8.46个月(IQR 3.18-16.89),长期数据有待观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to evaluate technical/clinical outcomes of the Gore TAG Conformable Thoracic Stent Graft with Active Control System (CTAG with ACS) in thoracic aortic disease since its introduction in Europe in 2017. METHODS: Patients undergoing thoracic endovascular aortic repair (TEVAR) with the device between 2017 and 2020 were identified from a prospectively maintained single-centre database and retrospectively analysed. Predominant indications were aortic dissection (n = 46), thoracic/thoraco-abdominal aneurysm (n = 20/n = 7), penetrating ulcer (n = 14) and intramural haematoma (n = 12). Emergency procedures were performed in 47% (54/115). The primary outcome was technical success. Secondary outcomes were clinical success, serious adverse events and procedure-related reintervention. ACS was assessed regarding angulation, accuracy and apposition. The median follow-up was 8.46 months (interquartile range: 3.18-16.89 months). RESULTS: A total of 115 consecutive patients (82 males, median age 63; interquartile range: 53-74 years) have been included. Technical success was achieved in 95.7% (110/115). Clinical success rate was 80.9% (93/115); mostly due to procedure-related death (n = 14). Overall mortality was 19.1% (22/115), with significant differences between elective/emergency procedures (log-rank: P < 0.001). Procedure-related serious adverse event rate was 44.3% (51/115). Procedure-related reintervention was performed in 20.9% (24/115). The cumulative incidence for reintervention differed significantly between elective/emergency cases (Gray's test: P = 0.0033). Angulation was used in 40.9% of patients (47/115), mostly in type II arches (52.7%). Deployment accuracy was 87.8% (101/115). Sufficient apposition was present in 93.0% (107/115). CONCLUSIONS: This single-centre study shows encouraging performance of the CTAG with ACS in an array of aortic pathologies. Although longer-term data must be awaited, ACS leads to overall favourable device placement. Despite ongoing advances in device technology, TEVAR remains challenging and is associated with significant burden inherent to the underlying disease.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Böckler D, Bischoff MS, Kronsteiner D, et al. Outcome analysis of the Gore Conformable Thoracic Stent Graft with active control system for the treatment of arch and descending thoracic aortic disease. Eur J Cardiothorac Surg. 2021. PMID: 34337659. doi:10.1093/ejcts/ezab289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。